Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Yukiko YoshidaLaboratory of Protein Metabolism, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.ORCID 0000-0002-0629-0219
Meari OkadaLaboratory of Protein Metabolism, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Naoko AraiLaboratory of Protein Metabolism, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Chikara AndoLaboratory of Protein Metabolism, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Daiki KinoshitaLaboratory of Protein Metabolism, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.ORCID 0009-0009-3952-6513
Yasumasa NishitoTechnology Research Division, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Fuyuki KametaniDementia Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.ORCID 0000-0001-9125-7001
Masato HasegawaDementia Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Keiji TanakaLaboratory of Protein Metabolism, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Akinori EndoLaboratory of Protein Metabolism, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Funding
Japan Agency for Medical Research and Development (AMED) JP23/24gm14100003Japan Agency for Medical Research and Development (AMED) JP24gm6410012MEXT | Japan Society for the Promotion of Science (JSPS) JP22H00419MEXT | Japan Society for the Promotion of Science (JSPS) JP22H02305MEXT | JST | Creations of Advanced Catalytic Transformation for the Sustainable Manufacturing at Low Energy, Low Environmental Load (ACT-C) JPMJCR16H3
6 · The paper itself
Abstract
Nuclear factor erythroid 2-like 1 (NFE2L1/Nrf1), an endoplasmic reticulum (ER)-associated transcription factor, is responsible for the coordinated expression of proteasome subunit genes upon proteasomal dysfunction.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
NFE2L1/Nrf1 forms a coactivator complex post-peptide: · full record | Socratic